fluorouracil has been researched along with Acute Liver Injury, Drug-Induced in 91 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Excerpt | Relevance | Reference |
---|---|---|
"An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 8.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
"To assess if CT texture analysis (TA) can serve as a biomarker of liver toxicity in patients with colorectal cancer treated with 5-fluorouracil (5-FU)-based chemotherapy." | 7.91 | 5-Fluorouracil induced liver toxicity in patients with colorectal cancer: role of computed tomography texture analysis as a potential biomarker. ( Alessandrino, F; Cruz, G; Meyerhardt, JA; Qin, L; Rosenthal, MH; Sahu, S; Shinagare, AB, 2019) |
"Assessment of oxaliplatin-associated hepatotoxicity in patients receiving oxaliplatin, fluorouracil and leucovorin chemotherapy (FOLFOX) for colorectal cancer remains controversial." | 7.81 | Serum Type IV Collagen Concentration Correlates with Indocyanine Green Retention Rate and is an Indicator Of Hepatotoxicity In Patients Receiving FOLFOX for Colorectal Cancer. ( Fujino, S; Hosokawa, Y; Katsumata, K; Makino, H; Maruno, K; Mushiake, H; Sugiyama, Y; Watanabe, M, 2015) |
"We have described fatty liver, diagnosed by computed tomography scanning (CT) in more than 30% of patients with breast cancer who received tamoxifen." | 7.70 | Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. ( Hamada, N; Inomata, T; Kariya, S; Murata, Y; Nishioka, A; Ogawa, Y; Saibara, T; Terashima, M; Yoshida, S, 2000) |
"Liver function tests from 194 breast cancer patients who received adjuvant chemotherapy with or without tamoxifen (TAM) were reviewed." | 6.68 | Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen. ( Hirvikoski, PP; Johansson, RT; Kumpulainen, EJ, 1997) |
"5-Fluorouracil was infused for 15 min into the hepatic artery or the saphenous vein of rats at a dose of 1." | 5.36 | Effect of acute hepatic failure on the hepatic first-pass effect of 5-fluorouracil in rats. ( Arimori, K; Hidaka, M; Hidaka, Y; Iwakiri, T; Kawano, Y; Nagata, M; Okumura, M, 2010) |
" Following intravenous administration of S-1, the blood concentration-time profiles of CDHP were similar between control rats and rats with hepatic dysfunction, but the half-life of tegafur was significantly prolonged." | 5.35 | Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats. ( Chikamoto, J; Kanie, S; Nagayama, S; Nishimura, T; Yoshisue, K, 2009) |
"An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 4.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
"To assess if CT texture analysis (TA) can serve as a biomarker of liver toxicity in patients with colorectal cancer treated with 5-fluorouracil (5-FU)-based chemotherapy." | 3.91 | 5-Fluorouracil induced liver toxicity in patients with colorectal cancer: role of computed tomography texture analysis as a potential biomarker. ( Alessandrino, F; Cruz, G; Meyerhardt, JA; Qin, L; Rosenthal, MH; Sahu, S; Shinagare, AB, 2019) |
"Assessment of oxaliplatin-associated hepatotoxicity in patients receiving oxaliplatin, fluorouracil and leucovorin chemotherapy (FOLFOX) for colorectal cancer remains controversial." | 3.81 | Serum Type IV Collagen Concentration Correlates with Indocyanine Green Retention Rate and is an Indicator Of Hepatotoxicity In Patients Receiving FOLFOX for Colorectal Cancer. ( Fujino, S; Hosokawa, Y; Katsumata, K; Makino, H; Maruno, K; Mushiake, H; Sugiyama, Y; Watanabe, M, 2015) |
"Assessment of oxaliplatin-associated hepatotoxicity in patients receiving oxaliplatin, fluorouracil and leucovorin chemotherapy (FOLFOX) for colorectal cancer remains controversial." | 3.81 | Serum Type IV Collagen Concentration Correlates with Indocyanine Green Retention Rate. ( Fujino, S; Hosokawa, Y; Katsumata, K; Makino, H; Maruno, K; Mushiake, H; Sugiyama, Y; Watanabe, M, 2015) |
"Atorvastatin prevented mucosal damage and inflammation associated with 5-FU-induced OM, but the association of a higher dose of ATV with 5-FU induced hepatotoxicity and amplified leukopenia." | 3.77 | Effect of atorvastatin on 5-fluorouracil-induced experimental oral mucositis. ( Alencar, NM; Barboza, DR; Brito, GA; Gomes, AS; Leitão, RF; Macedo, RN; Medeiros, CA; Nogueira, NA; Ribeiro, RA, 2011) |
"Bevacizumab (Avastin) in combination with intravenous 5-fluorouracil-based chemotherapy as first-line as well as second-line treatment of metastatic colorectal cancer improves survival." | 3.73 | Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. ( Gotlib, V; Khaled, S; Lapko, I; Mar, N; Saif, MW, 2006) |
"We have described fatty liver, diagnosed by computed tomography scanning (CT) in more than 30% of patients with breast cancer who received tamoxifen." | 3.70 | Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. ( Hamada, N; Inomata, T; Kariya, S; Murata, Y; Nishioka, A; Ogawa, Y; Saibara, T; Terashima, M; Yoshida, S, 2000) |
" In the present study the therapeutic effect and metabolism of 5-FU and its masked compounds: FT, UFT (uracil + FT), HCFU (Carmofur), 5'-DFUR (Doxifluridine) were assessed by using MOPC-104E plasmacytoma transplanted subcutaneously in BALB/c mice with CCl4-induced chronic liver dysfunction." | 3.68 | [Chemotherapy with fluoropyrimidines for MOPC-104E plasmacytoma transplanted in mice with CCl4 induced chronic liver dysfunction]. ( Imai, S; Morimoto, H; Nio, Y; Shiraishi, T; Tobe, T; Tseng, CC; Tsubono, M, 1990) |
"As adverse reactions to the combination treatment by the digestive system, we observed the occurrence of nausea and vomiting in 15% of the cases who received FTP treatment consisting of 5-FU, toyomicin and prednisone, 25% of the cases who received MFU treatment consisting of MMC, 5-FU and ACNU, and in 64% of the cases who received PPQ treatment consisting of CDDP, Carboquone (CQ) and prednisone." | 3.67 | [Adverse reactions to carcinostatics and countermeasures]. ( Nakao, I, 1989) |
"5 mg/kg of mitomycin-C (Mit-C) resulted in 70% (n = 20) and 71% (n = 14) mortality, respectively, from 2 to 7 days after perfusion, with extensive, patchy necrosis and infarction seen on histologic examination and markedly elevated levels of serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) at 6 and 24 hours after perfusion." | 3.66 | Reversal of lethal, chemotherapeutically induced acute hepatic necrosis in rats by regenerating liver cytosol. ( Falk, JA; Falk, RE; Falk, W; Makowka, L; Miyazaki, M; Venturi, D, 1983) |
"Patients with Stage II/III gastric cancer after surgery were recruited." | 2.76 | Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen). ( Bi, F; Cao, D; Gou, HF; He, B; Li, Q; Li, ZP; Liao, ZY; Liu, JY; Luo, DY; Qiu, M; Shen, YL; Wang, X; Wang, Y; Xu, F; Yang, Y; Yi, C, 2011) |
"Liver function tests from 194 breast cancer patients who received adjuvant chemotherapy with or without tamoxifen (TAM) were reviewed." | 2.68 | Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen. ( Hirvikoski, PP; Johansson, RT; Kumpulainen, EJ, 1997) |
"Fifty-seven Dukes C colorectal cancer patients were given 5-fluorouracil-interferon-alpha 2b adjuvant treatment from October 1986 to September 1990." | 2.67 | 5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer. ( Cremone, L; Espinosa, A; Faiella, F; Frasci, G; Leone, F; Monaco, M; Persico, G; Sapio, U, 1994) |
"5-fluorouracil (5-FU) is a widely used chemotherapeutic drug, but its hepatotoxicity challenges its clinical use." | 1.72 | Role of Platelet-activating factor and HO-1 in mediating the protective effect of rupatadine against 5-fluorouracil-induced hepatotoxicity in rats. ( Abdalla, AM; Abdelbaky, FAF; Abdelzaher, WY; Hafez, SMNA; Khalaf, HM; Welson, NN, 2022) |
"5- Fluorouracil (5-FU) is a conventional and most effective drug used in the clinic for the treatment of CRC." | 1.72 | Sulfonamide-Functionalized Polymeric Nanoparticles for Enhanced In Vivo Colorectal Cancer Therapy. ( Andrade, SP; Campos, PP; Gontijo, SML; Guimarães, PPG; Pereira, L; Santos, RAS; Sinisterra, RD; Viana, CTR, 2022) |
"Juglone has been showed to exert a direct cytotoxic effect on tumor cells." | 1.51 | Juglone eliminates MDSCs accumulation and enhances antitumor immunity. ( Cui, Y; E, F; Gao, X; Qiu, Z; Wang, H; Yu, Y; Zhang, H; Zhao, W; Zou, C, 2019) |
"Two cohorts of metastatic colorectal cancer (CRC) were analyzed: a nonrandomized exploratory cohort of 184 patients treated at a single institution from 2003 to 2010 and a confirmatory cohort of 200 patients from a multi-institutional randomized trial (NO16966)." | 1.48 | The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. ( Ferrarotto, R; George, B; Hobbs, B; Hoff, PM; Kopetz, S; Loyer, EM; Machado, KK; Mazard, T; Overman, MJ; Qiao, W; Raghav, K; Saltz, LB; Vauthey, JN, 2018) |
"5-Fluorouracil (5-FU) is a pyrimidine analog widely used for the treatment of various cancers, but often causes hepatic damage in clinical practice." | 1.43 | Taurine as a protective agent for 5-fluorouracil-induced hepatic damage related to oxidative stress. ( Fukuno, S; Konishi, H; Nagai, K; Suzuki, H; Yoshida, S, 2016) |
"Chemotherapy-induced toxic liver injury is a relevant issue in the clinical management of patients affected with metastatic colorectal cancer (mCRC)." | 1.42 | Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience. ( Fausti, V; Gallo, P; Imperatori, M; Picardi, A; Santini, D; Spalato Ceruso, M; Tonini, G; Vespasiani Gentilucci, U; Vincenzi, B, 2015) |
"Close monitoring and prompt discontinuation of the drugs with high volume of distribution and metabolized through the liver are necessary to avoid drug-drug interaction in liver transplant patients." | 1.40 | Liver injury possibly related to drug interaction after liver transplant: a case report. ( Jiang, WT; Liu, YH; Pan, C; Thian, Y; Zhu, LQ, 2014) |
"Patients undergoing liver resection for colorectal cancer liver metastasis (CRCLM) are often treated with chemotherapy before surgery." | 1.39 | Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. ( Allen, PJ; Bao, F; D'Angelica, MI; DeMatteo, RP; Fong, Y; Gönen, M; Jarnagin, WR; Kemeny, N; Kingham, TP; Park, JO; Shia, J; Wolf, PS, 2013) |
" The incidences of grade 3 or 4 adverse events and grade 2 or greater histopathological sinusoidal injury were significantly higher in the SVI ≥ +30% than in the SVI < +30% group." | 1.37 | Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. ( Arai, T; Kobayashi, S; Koike, J; Koizumi, S; Makizumi, R; Miura, K; Miyajima, N; Nakano, H; Otsubo, T; Sakurai, J; Shimamura, T; Yamada, K, 2011) |
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems." | 1.36 | Developing structure-activity relationships for the prediction of hepatotoxicity. ( Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010) |
"5-Fluorouracil was infused for 15 min into the hepatic artery or the saphenous vein of rats at a dose of 1." | 1.36 | Effect of acute hepatic failure on the hepatic first-pass effect of 5-fluorouracil in rats. ( Arimori, K; Hidaka, M; Hidaka, Y; Iwakiri, T; Kawano, Y; Nagata, M; Okumura, M, 2010) |
" Following intravenous administration of S-1, the blood concentration-time profiles of CDHP were similar between control rats and rats with hepatic dysfunction, but the half-life of tegafur was significantly prolonged." | 1.35 | Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats. ( Chikamoto, J; Kanie, S; Nagayama, S; Nishimura, T; Yoshisue, K, 2009) |
"The subjects were 13 colorectal cancer patients who had undergone resection of the primary tumor, and showed multiple, unresectable liver metastases and severe liver dysfunction." | 1.35 | [Combination of hepatic arterial infusion therapy and FOLFOX for colorectal cancer with multiple unresectable liver metastases causing severe liver dysfunction]. ( Iizawa, H; Ikeda, E; Ishiyama, K; Mori, N; Saito, K; Sakurai, N; Sato, T; Suto, T; Takano, N, 2009) |
"All patients died from neoplastic disease progression despite further chemotherapy at 6, 17 and 31 months following the diagnosis of NRH." | 1.34 | Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? ( Canon, JL; Ceratti, A; Gigot, JF; Horsmans, Y; Hubert, C; Humblet, Y; Machiels, JP; Rahier, J; Sempoux, C, 2007) |
" However, it was repeatedly shown that the sequence of 5-FU followed by CDDP is more active and less toxic in tumor-bearing animals." | 1.33 | Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice. ( Fujimoto, S, 2006) |
"In the patients with squamous cell carcinoma, 100 mg/m2 of cisplatin was infused intravenously, followed immediately by five consecutive daily administrations of 5-fluorouracil, 1,000 mg/m2/day, each infused intravenously over 24 hr." | 1.31 | Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors. ( Kim, GE; Kim, SN; Kim, SW; Park, TK; Suh, CO, 2000) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 18 (19.78) | 18.7374 |
1990's | 14 (15.38) | 18.2507 |
2000's | 9 (9.89) | 29.6817 |
2010's | 47 (51.65) | 24.3611 |
2020's | 3 (3.30) | 2.80 |
Authors | Studies |
---|---|
Fourches, D | 1 |
Barnes, JC | 1 |
Day, NC | 1 |
Bradley, P | 1 |
Reed, JZ | 1 |
Tropsha, A | 1 |
Greene, N | 1 |
Fisk, L | 1 |
Naven, RT | 1 |
Note, RR | 1 |
Patel, ML | 1 |
Pelletier, DJ | 1 |
Morgan, RE | 2 |
Trauner, M | 1 |
van Staden, CJ | 2 |
Lee, PH | 1 |
Ramachandran, B | 1 |
Eschenberg, M | 1 |
Afshari, CA | 2 |
Qualls, CW | 1 |
Lightfoot-Dunn, R | 1 |
Hamadeh, HK | 2 |
Ekins, S | 1 |
Williams, AJ | 1 |
Xu, JJ | 1 |
Liu, Z | 1 |
Shi, Q | 1 |
Ding, D | 1 |
Kelly, R | 1 |
Fang, H | 1 |
Tong, W | 2 |
Warner, DJ | 1 |
Chen, H | 1 |
Cantin, LD | 1 |
Kenna, JG | 1 |
Stahl, S | 1 |
Walker, CL | 1 |
Noeske, T | 1 |
Chen, Y | 1 |
Kalyanaraman, N | 1 |
Kalanzi, J | 1 |
Dunn, RT | 1 |
Chen, M | 1 |
Suzuki, A | 1 |
Thakkar, S | 1 |
Yu, K | 1 |
Hu, C | 1 |
Khalaf, HM | 1 |
Hafez, SMNA | 1 |
Abdalla, AM | 1 |
Welson, NN | 1 |
Abdelzaher, WY | 1 |
Abdelbaky, FAF | 1 |
Shindoh, J | 1 |
Kobayashi, Y | 1 |
Kinowaki, K | 1 |
Mise, Y | 1 |
Gonoi, W | 1 |
Yoshida, S | 3 |
Tani, K | 1 |
Matoba, S | 1 |
Kuroyanagi, H | 1 |
Hashimoto, M | 1 |
Sarathy, V | 1 |
Kothandath Shankar, RK | 1 |
Mufti, SS | 1 |
Naik, R | 1 |
Guimarães, PPG | 1 |
Viana, CTR | 1 |
Pereira, L | 1 |
Gontijo, SML | 1 |
Campos, PP | 1 |
Andrade, SP | 1 |
Santos, RAS | 1 |
Sinisterra, RD | 1 |
Duwe, G | 1 |
Knitter, S | 1 |
Pesthy, S | 1 |
Beierle, AS | 1 |
Bahra, M | 1 |
Schmelzle, M | 1 |
Schmuck, RB | 1 |
Lohneis, P | 1 |
Raschzok, N | 1 |
Öllinger, R | 1 |
Sinn, M | 1 |
Struecker, B | 1 |
Sauer, IM | 1 |
Pratschke, J | 1 |
Andreou, A | 1 |
Overman, MJ | 1 |
Ferrarotto, R | 1 |
Raghav, K | 1 |
George, B | 1 |
Qiao, W | 1 |
Machado, KK | 1 |
Saltz, LB | 1 |
Mazard, T | 1 |
Vauthey, JN | 1 |
Hoff, PM | 1 |
Hobbs, B | 1 |
Loyer, EM | 1 |
Kopetz, S | 1 |
Akindele, AJ | 1 |
Oludadepo, GO | 1 |
Amagon, KI | 1 |
Singh, D | 1 |
Osiagwu, DD | 1 |
Ünal, E | 1 |
Karaosmanoğlu, AD | 1 |
Ozmen, MN | 1 |
Akata, D | 1 |
Karcaaltincaba, M | 1 |
Fukuno, S | 1 |
Nagai, K | 1 |
Suzuki, H | 1 |
Konishi, H | 1 |
Hajj, A | 1 |
Ghosn, M | 1 |
Mourad, D | 1 |
Hojaiban, K | 1 |
Mousallem, P | 1 |
Khabbaz, LR | 1 |
Hubert, C | 2 |
Lucidi, V | 1 |
Weerts, J | 1 |
Dili, A | 1 |
Demetter, P | 1 |
Massart, B | 1 |
Komuta, M | 1 |
Navez, J | 1 |
Reding, R | 1 |
Gigot, JF | 2 |
Sempoux, C | 2 |
Li, PJ | 1 |
Mo, HY | 1 |
Luo, DH | 1 |
Hu, WH | 1 |
Jin, T | 1 |
Munakata, C | 1 |
Fuchigami, Y | 1 |
Hiroishi, S | 1 |
Haraguchi, A | 1 |
Hagimori, M | 1 |
Enomoto, H | 1 |
Tachiki, H | 1 |
Kodama, Y | 1 |
Sasaki, H | 1 |
Kawakami, S | 1 |
Limaiem, F | 1 |
Bouraoui, S | 1 |
Wang, H | 1 |
Zou, C | 2 |
Zhao, W | 1 |
Yu, Y | 1 |
Cui, Y | 1 |
Zhang, H | 1 |
E, F | 1 |
Qiu, Z | 1 |
Gao, X | 1 |
Alessandrino, F | 1 |
Qin, L | 1 |
Cruz, G | 1 |
Sahu, S | 1 |
Rosenthal, MH | 1 |
Meyerhardt, JA | 1 |
Shinagare, AB | 1 |
Robinson, SM | 2 |
Mann, J | 2 |
Manas, DM | 2 |
Mann, DA | 2 |
White, SA | 2 |
Gurzu, S | 1 |
Jung, I | 1 |
Comsulea, M | 1 |
Kadar, Z | 1 |
Azamfirei, L | 1 |
Molnar, C | 1 |
Oakley, F | 1 |
Liu, Y | 1 |
Wu, W | 1 |
Hong, W | 1 |
Sun, X | 1 |
Wu, J | 1 |
Huang, Q | 1 |
Han, NY | 1 |
Park, BJ | 1 |
Sung, DJ | 1 |
Kim, MJ | 1 |
Cho, SB | 1 |
Lee, CH | 1 |
Jang, YJ | 1 |
Kim, SY | 1 |
Kim, DS | 1 |
Um, SH | 1 |
Won, NH | 1 |
Yang, KS | 1 |
Zhu, LQ | 1 |
Jiang, WT | 1 |
Pan, C | 1 |
Liu, YH | 1 |
Thian, Y | 1 |
Poornima, K | 1 |
Chella Perumal, P | 1 |
Gopalakrishnan, VK | 1 |
Yan, Y | 1 |
Mo, Y | 1 |
Zhang, D | 1 |
Vincenzi, B | 3 |
Imperatori, M | 1 |
Picardi, A | 3 |
Vespasiani Gentilucci, U | 1 |
Gallo, P | 1 |
Fausti, V | 1 |
Spalato Ceruso, M | 1 |
Santini, D | 2 |
Tonini, G | 3 |
Hosokawa, Y | 2 |
Watanabe, M | 2 |
Makino, H | 2 |
Mushiake, H | 2 |
Katsumata, K | 2 |
Maruno, K | 2 |
Fujino, S | 2 |
Sugiyama, Y | 2 |
Hiroshima, Y | 1 |
Shuto, K | 1 |
Yamazaki, K | 1 |
Kawaguchi, D | 1 |
Yamada, M | 1 |
Kikuchi, Y | 1 |
Kasahara, K | 1 |
Murakami, T | 1 |
Hirano, A | 1 |
Mori, M | 1 |
Kosugi, C | 1 |
Matsuo, K | 1 |
Ishida, Y | 1 |
Koda, K | 1 |
Tanaka, K | 1 |
Suto, T | 1 |
Sato, T | 1 |
Mori, N | 1 |
Takano, N | 1 |
Ishiyama, K | 1 |
Sakurai, N | 1 |
Saito, K | 1 |
Iizawa, H | 1 |
Ikeda, E | 1 |
Yoshisue, K | 1 |
Kanie, S | 1 |
Nishimura, T | 1 |
Chikamoto, J | 1 |
Nagayama, S | 1 |
Nagata, M | 1 |
Hidaka, Y | 1 |
Hidaka, M | 1 |
Kawano, Y | 1 |
Iwakiri, T | 1 |
Okumura, M | 1 |
Arimori, K | 1 |
Medeiros, CA | 1 |
Leitão, RF | 1 |
Macedo, RN | 1 |
Barboza, DR | 1 |
Gomes, AS | 1 |
Nogueira, NA | 1 |
Alencar, NM | 1 |
Ribeiro, RA | 1 |
Brito, GA | 1 |
Mikalauskas, S | 1 |
Mikalauskiene, L | 1 |
Bruns, H | 1 |
Nickkholgh, A | 1 |
Hoffmann, K | 1 |
Longerich, T | 1 |
Strupas, K | 1 |
Büchler, MW | 1 |
Schemmer, P | 1 |
Wang, X | 1 |
Wang, Y | 1 |
Qiu, M | 1 |
Li, Q | 1 |
Li, ZP | 1 |
He, B | 1 |
Xu, F | 1 |
Shen, YL | 1 |
Gou, HF | 1 |
Yang, Y | 1 |
Cao, D | 1 |
Yi, C | 1 |
Liu, JY | 1 |
Luo, DY | 1 |
Liao, ZY | 1 |
Bi, F | 1 |
Krieger, PM | 1 |
Tamandl, D | 1 |
Herberger, B | 1 |
Faybik, P | 1 |
Fleischmann, E | 1 |
Maresch, J | 1 |
Gruenberger, T | 1 |
Daniele, S | 1 |
Frezza, AM | 2 |
Berti, P | 2 |
Vespasiani, U | 2 |
Miura, K | 1 |
Nakano, H | 1 |
Sakurai, J | 1 |
Kobayashi, S | 1 |
Koizumi, S | 1 |
Arai, T | 1 |
Shimamura, T | 1 |
Makizumi, R | 1 |
Yamada, K | 1 |
Miyajima, N | 1 |
Otsubo, T | 1 |
Koike, J | 1 |
Pilgrim, CH | 1 |
Brettingham-Moore, K | 1 |
Pham, A | 1 |
Murray, W | 1 |
Link, E | 1 |
Smith, M | 1 |
Usatoff, V | 1 |
Evans, PM | 1 |
Banting, S | 1 |
Thomson, BN | 1 |
Michael, M | 1 |
Phillips, WA | 1 |
Ramachandran, S | 1 |
Mandal, M | 1 |
Vietor, NO | 1 |
George, BJ | 1 |
Wolf, PS | 1 |
Park, JO | 1 |
Bao, F | 1 |
Allen, PJ | 1 |
DeMatteo, RP | 1 |
Fong, Y | 1 |
Jarnagin, WR | 1 |
Kingham, TP | 1 |
Gönen, M | 1 |
Kemeny, N | 1 |
Shia, J | 1 |
D'Angelica, MI | 1 |
Tzeng, CW | 1 |
Aloia, TA | 1 |
Makino, S | 1 |
Murata, K | 1 |
Murakami, M | 1 |
Wada, Y | 1 |
Kato, R | 1 |
Nishigaki, T | 1 |
Owada, Y | 1 |
Okada, K | 1 |
Yanagisawa, T | 1 |
Okamura, S | 1 |
Ebisui, C | 1 |
Yokouchi, H | 1 |
Kinuta, M | 1 |
Nakagomi, N | 1 |
Tamai, M | 1 |
Gotlib, V | 1 |
Khaled, S | 1 |
Lapko, I | 1 |
Mar, N | 1 |
Saif, MW | 1 |
Fujimoto, S | 1 |
Horsmans, Y | 1 |
Rahier, J | 1 |
Humblet, Y | 1 |
Machiels, JP | 1 |
Ceratti, A | 1 |
Canon, JL | 1 |
Miyazaki, M | 1 |
Makowka, L | 1 |
Falk, RE | 1 |
Falk, JA | 1 |
Falk, W | 1 |
Venturi, D | 1 |
Schlangen, J | 1 |
Wils, J | 1 |
Savrin, RA | 1 |
Martin, EW | 1 |
Frasci, G | 1 |
Leone, F | 1 |
Monaco, M | 1 |
Cremone, L | 1 |
Sapio, U | 1 |
Faiella, F | 1 |
Espinosa, A | 1 |
Persico, G | 1 |
Klotz, HP | 1 |
Weder, W | 1 |
Largiadèr, F | 1 |
Moertel, CG | 1 |
Fleming, TR | 1 |
Macdonald, JS | 1 |
Haller, DG | 1 |
Laurie, JA | 1 |
Uchino, J | 1 |
Une, Y | 1 |
Sato, Y | 1 |
Gondo, H | 1 |
Nakajima, Y | 1 |
Sato, N | 1 |
Hirvikoski, PP | 1 |
Kumpulainen, EJ | 1 |
Johansson, RT | 1 |
Valik, D | 1 |
Kimura, Y | 1 |
Okuda, H | 1 |
Locatelli, M | 1 |
Colleoni, M | 1 |
Noberasco, C | 1 |
Nolé, F | 1 |
Orlando, L | 1 |
Munzone, E | 1 |
Peruzzotti, G | 1 |
Goldhirsch, A | 1 |
Yamano, T | 1 |
Takayasu, Y | 1 |
Nakao, N | 1 |
Kubota, A | 1 |
Soori, GS | 1 |
Oldham, RK | 1 |
Dobbs, TW | 1 |
Bury, MJ | 1 |
Church, CK | 1 |
DePriest, C | 1 |
Park, TK | 1 |
Kim, SN | 1 |
Kim, SW | 1 |
Kim, GE | 1 |
Suh, CO | 1 |
Hamada, N | 1 |
Ogawa, Y | 1 |
Saibara, T | 1 |
Murata, Y | 1 |
Kariya, S | 1 |
Nishioka, A | 1 |
Terashima, M | 1 |
Inomata, T | 1 |
Chabner, BA | 1 |
Myers, CE | 2 |
Coleman, CN | 1 |
Johns, DG | 1 |
Stenram, U | 1 |
Kemeny, NE | 1 |
Harada, M | 1 |
Koga, K | 1 |
Miura, I | 1 |
Nishitani, H | 1 |
Tsubono, M | 2 |
Nio, Y | 2 |
Imai, S | 2 |
Shiraishi, T | 2 |
Morimoto, H | 2 |
Tseng, CC | 2 |
Kawabata, K | 1 |
Fukumoto, M | 1 |
Tobe, T | 2 |
Schlag, P | 1 |
Yi, J | 1 |
Friedl, P | 1 |
Hull, W | 1 |
Berger, M | 1 |
Nakao, I | 1 |
Lorenz, M | 1 |
Hottenrott, C | 1 |
Inglis, R | 1 |
Kirkowa-Reimann, M | 1 |
Patakfalvi, A | 2 |
Gelencsér, E | 2 |
Sípos, J | 2 |
Caruso, U | 1 |
Elli, M | 1 |
Cravotto, E | 1 |
Tisone, G | 1 |
Lombardo, PA | 1 |
Silvaroli, M | 1 |
Ficorella, C | 1 |
Cortesi, E | 1 |
Casciani, CU | 1 |
Sugarbaker, PH | 1 |
Gianola, FJ | 1 |
Speyer, JL | 1 |
Wesley, R | 1 |
Barofsky, I | 1 |
Kitamura, M | 1 |
Tominaga, T | 1 |
Hayashi, K | 1 |
Takahashi, I | 1 |
Kosaki, G | 1 |
Kemeny, MM | 1 |
Goldberg, DA | 1 |
Browning, S | 1 |
Metter, GE | 1 |
Miner, PJ | 1 |
Terz, JJ | 1 |
Gorgun, B | 1 |
Watne, AL | 1 |
Poliak, NR | 1 |
Vestfrid, MA | 1 |
Castelleto, L | 1 |
Giménez, PO | 1 |
Tsoĭ, AI | 1 |
Dement'eva, NI | 1 |
Sulaeva, LS | 1 |
Ambre, JJ | 1 |
Fischer, LJ | 1 |
Pivniuk, VM | 1 |
Buklina, ZP | 1 |
Ezerskaia, LIa | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
8 reviews available for fluorouracil and Acute Liver Injury, Drug-Induced
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemical and D | 2017 |
Hepatobiliary phase liver MR imaging findings after Oxaliplatin-based chemotherapy in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical and Dru | 2018 |
Raltitrexed-based chemotherapy for advanced colorectal cancer.
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Chemical and Drug Induce | 2014 |
Oxaliplatin-induced hepatocellular injury and ototoxicity: a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Inju | 2012 |
Colorectal liver metastases.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablati | 2013 |
The clinical pharmacology of antineoplastic agents (first of two parts).
Topics: Animals; Antineoplastic Agents; Asparaginase; Binding Sites; Biological Transport; Chemical and Drug | 1975 |
Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes!
Topics: Actuarial Analysis; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Dexamethasone; Fl | 1992 |
13 trials available for fluorouracil and Acute Liver Injury, Drug-Induced
Article | Year |
---|---|
[Magnesium isoglycyrrhizinate prevention of chemotherapy-induced liver damage during initial treatment of patients with gastrointestinal tumors].
Topics: Alanine Transaminase; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Aspartat | 2015 |
Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Chemo | 2011 |
5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer.
Topics: Aged; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Colonic Neoplasms; Confidence | 1994 |
Local and systemic toxicity of intra-hepato-arterial chemotherapy for treatment of unresectable liver metastases of colorectal cancer with 5-Fluorouracil and high dose Leucovorin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Colore | 1993 |
Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemical and Drug Induced Liver Injury; Chem | 1993 |
Chemohormonal therapy of unresectable hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 1993 |
Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen.
Topics: Acetyltransferases; Adult; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Antineoplastic Com | 1997 |
Chemo-biotherapy with 5-fluorouracil, leucovorin, and alpha interferon in metastatic carcinoma of the colon--a Cancer Biotherapy Research Group [CBRG] phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2000 |
Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes!
Topics: Actuarial Analysis; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Dexamethasone; Fl | 1992 |
Prevention of extrahepatic disease during intraarterial floxuridine of colorectal liver metastases by simultaneous systemic 5-fluorouracil treatment? A prospective multicenter study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Inju | 1989 |
Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer.
Topics: Adult; Catheters, Indwelling; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Colo | 1985 |
[Preliminary report of adjuvant chemo-endocrine therapy for breast cancer].
Topics: Adult; Anorexia; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Combined Modality Therapy | 1985 |
Experience with continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. A prospective randomized study.
Topics: Chemical and Drug Induced Liver Injury; Cholestasis; Colonic Neoplasms; Combined Modality Therapy; F | 1985 |
71 other studies available for fluorouracil and Acute Liver Injury, Drug-Induced
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Role of Platelet-activating factor and HO-1 in mediating the protective effect of rupatadine against 5-fluorouracil-induced hepatotoxicity in rats.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Chemical and Drug Induced | 2022 |
Dynamic Changes in Normal Liver Parenchymal Volume During Chemotherapy for Colorectal Cancer: Liver Atrophy as an Alternate Marker of Chemotherapy-Associated Liver Injury.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Bevacizumab | 2019 |
FOLFOX and capecitabine-induced hepatic granuloma mimicking metastasis in a rectal cancer patient.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemi | 2020 |
Sulfonamide-Functionalized Polymeric Nanoparticles for Enhanced In Vivo Colorectal Cancer Therapy.
Topics: Chemical and Drug Induced Liver Injury; Colonic Neoplasms; Drug Carriers; Drug Delivery Systems; Flu | 2022 |
The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemica | 2018 |
Protective effect of carvedilol alone and coadministered with diltiazem and prednisolone on doxorubicin and 5-fluorouracil-induced hepatotoxicity and nephrotoxicity in rats.
Topics: Acute Kidney Injury; Animals; Antibiotics, Antineoplastic; Carbazoles; Carvedilol; Chemical and Drug | 2018 |
Taurine as a protective agent for 5-fluorouracil-induced hepatic damage related to oxidative stress.
Topics: Animals; Antimetabolites, Antineoplastic; Chemical and Drug Induced Liver Injury; Dose-Response Rela | 2016 |
Lethal hepatotoxicity following 5-fluorouracil/cisplatin chemotherapy: a relevant case report.
Topics: Aged; Chemical and Drug Induced Liver Injury; Cisplatin; Drug-Related Side Effects and Adverse React | 2017 |
Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Chemo | 2018 |
Evaluation of miR-122 to Predict High Dose Acetaminophen-Induced Liver Injury in Mice: The Combination Uses of 5-Fluorouracil.
Topics: Acetaminophen; Alanine Transaminase; Analgesics, Non-Narcotic; Animals; Antimetabolites, Antineoplas | 2018 |
Chemotherapy-induced liver injury in metastatic colorectal cancer: about 48 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2018 |
Juglone eliminates MDSCs accumulation and enhances antitumor immunity.
Topics: Animals; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chemical and Drug Indu | 2019 |
5-Fluorouracil induced liver toxicity in patients with colorectal cancer: role of computed tomography texture analysis as a potential biomarker.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers; Chemical and Drug Induced Liver Injury; Colorecta | 2019 |
An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Combined Chemotherapy Protocols; Cation Transport | 2013 |
Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman.
Topics: Acute Disease; Adenocarcinoma; Adult; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protoco | 2013 |
The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemical and Drug Induced | 2013 |
Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy: gadoxetic acid--enhanced and diffusion-weighted MR imaging with clinical-pathologic correlation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemica | 2014 |
Liver injury possibly related to drug interaction after liver transplant: a case report.
Topics: Adult; Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Chemical and Drug Induced Live | 2014 |
Protective effect of ethanolic extract of Tabernaemontana divaricata (L.) R. Br. against DEN and Fe NTA induced liver necrosis in Wistar Albino rats.
Topics: Alkylating Agents; Animals; Antimetabolites; Antioxidants; Bilirubin; Biomarkers; Carcinogens; Chemi | 2014 |
Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemic | 2015 |
Serum Type IV Collagen Concentration Correlates with Indocyanine Green Retention Rate and is an Indicator Of Hepatotoxicity In Patients Receiving FOLFOX for Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemical and Drug Induced Liver In | 2015 |
Serum Type IV Collagen Concentration Correlates with Indocyanine Green Retention Rate.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cohort | 2015 |
Fractal Dimension of Tc-99m DTPA GSA Estimates Pathologic Liver Injury due to Chemotherapy in Liver Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemic | 2016 |
[Combination of hepatic arterial infusion therapy and FOLFOX for colorectal cancer with multiple unresectable liver metastases causing severe liver dysfunction].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2009 |
Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Chemical and Drug Induced Liver Injury; Dihydroura | 2009 |
Effect of acute hepatic failure on the hepatic first-pass effect of 5-fluorouracil in rats.
Topics: Animals; Antineoplastic Agents; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Inju | 2010 |
Effect of atorvastatin on 5-fluorouracil-induced experimental oral mucositis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Atorvastatin; Bac | 2011 |
Dietary glycine protects from chemotherapy-induced hepatotoxicity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neo | 2011 |
Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2012 |
Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2011 |
The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotr | 2011 |
mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Dihydrouracil D | 2011 |
Induction of apoptosis of azurin synthesized from P. aeruginosa MTCC 2453 against Dalton's lymphoma ascites model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Pro | 2011 |
Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopla | 2013 |
[Liver damage detected after a hepatectomy for liver metastasis after 12 courses of mFOLFOX6 therapy as an adjuvant chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chemical and Drug Induced Liver Injury; C | 2012 |
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2006 |
Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carboplatin | 2006 |
Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Chemot | 2007 |
Reversal of lethal, chemotherapeutically induced acute hepatic necrosis in rats by regenerating liver cytosol.
Topics: Acute Disease; Animals; Chemical and Drug Induced Liver Injury; Cytosol; Fluorouracil; Hyperthermia, | 1983 |
Liver calcifications following hepatic artery infusion with 5-fluorouracil, adriamycin and mitomycin C (FAM).
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Chemical and Drug Induced Liver Injury; | 1984 |
The relationship of the possible hepatic toxicity of chemotherapeutic drugs and carcinoembryonic antigen elevation.
Topics: Adenocarcinoma; Biopsy; Carcinoembryonic Antigen; Chemical and Drug Induced Liver Injury; Fluorourac | 1981 |
Encephalopathy, lactic acidosis, hyperammonaemia and 5-fluorouracil toxicity.
Topics: Acidosis, Lactic; Ammonia; Brain Diseases; Chemical and Drug Induced Liver Injury; Citric Acid Cycle | 1998 |
Prevention by carp extract of myelotoxicity and gastrointestinal toxicity induced by 5-fluorouracil without loss of antitumor activity in mice.
Topics: Amino Acids; Animals; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Carps; Chemical and Dru | 1999 |
Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF regimen)
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver In | 1999 |
[Evaluation of hepatic toxicity following high-dose 5-FU arterial infusion chemotherapy: analysis of 42 cases of colorectal liver metastases].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Atrophy; Chemical and Drug Induced Liver Injury; Color | 2000 |
Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2000 |
Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
Topics: Alanine Transaminase; Alcohol Drinking; Antineoplastic Agents, Hormonal; Antineoplastic Combined Che | 2000 |
Hepatotoxicity of fluorouracil with N-phosphonacetyl-L-aspartate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Chemical and Drug Induced Liver Injur | 1992 |
A new method for the evaluation of the liver injury by 19F MRS of 5-fluorouracil.
Topics: Animals; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Fluorouracil; Liver | 1991 |
Low uracil concentration in the liver might be responsible for the decreased antineoplastic activity of fluoropyrimidines in mice with CCl4-induced chronic liver dysfunction.
Topics: Animals; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Drug Resistance; Fi | 1991 |
[Animal experiment studies of the toxicity of fluorodeoxyuridine (FUDR) and 5-fluorouracil (FU) within the scope of regional liver infusion chemotherapy].
Topics: Animals; Bile; Chemical and Drug Induced Liver Injury; Female; Floxuridine; Fluorouracil; Inactivati | 1990 |
[Chemotherapy with fluoropyrimidines for MOPC-104E plasmacytoma transplanted in mice with CCl4 induced chronic liver dysfunction].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbon Tetrachloride | 1990 |
[Adverse reactions to carcinostatics and countermeasures].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Chemical and Drug Indu | 1989 |
Drug hepatitis of cholestatic type in association with a FAC-regimen for breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced L | 1987 |
[Liver damage following combined cytostatic therapy of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver In | 1986 |
Colorectal cancer (Duke's group B2, C1, C2): adjuvant chemotherapy and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chemical and Drug Induced | 1985 |
Infusion chemotherapy in hepatoma and metastatic liver tumors.
Topics: Adenocarcinoma; Adolescent; Aged; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; | 1967 |
[Use of vitamin B-15 in experimental tumor chemotherapy].
Topics: Animals; Antineoplastic Agents; Carbon Tetrachloride Poisoning; Carcinoma; Chemical and Drug Induced | 1970 |
[Diffuse liver necrosis in treatment with 5-fluorouracil].
Topics: Adult; Chemical and Drug Induced Liver Injury; Fluorouracil; Humans; Liver; Male; Mesothelioma; Necr | 1972 |
[The functional state of the liver during conservative treatment of oncologic patients].
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Esophageal Neoplasms; Fluorouracil; H | 1972 |
The effect of prednisolone and other factors on the catabolism of 5-fluorouracil in rats.
Topics: Animals; Autoradiography; Carbon Dioxide; Carbon Isotopes; Carbon Tetrachloride Poisoning; Chemical | 1971 |
[Hematopoietic changes following use of fluorouracil in animals with toxic hepatitis].
Topics: Anemia, Aplastic; Animals; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; F | 1970 |